DYII, researcher, I am still pretty heavy in this one and think it has minimal downside with a pretty solid upside. I like the following facts:
1. Over $1.50/share in cash.
2. Even without all the cash, current assets exceed total liabilities.
3. In '06 and '07, the May quarter was 23-25% higher in gross revenue than the February quarter (some seasonality).
4. Even if in '08, the May quarter is only sequentially equal to February, I think EPS can be $.12 to $.16 for the quarter, which when combined with the solid balance sheet justifies the current share price IMO.
5. Growth is coming in the more expensive bariatric procedures.
6. The China discussions and spinoff don't excite me, but I still like DYII nonetheless.
Earnings should be out in a about a month, so we'll see. As SSKILLZ always says, I could always be wrong though.